In the first-in-human study of copanlisib, of 48 patients with advanced solid tumors, one patient with endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss achieved a CR, two metastatic breast cancer patients had a PR, and 15 patients achieved stable disease [20]. This evidence concerns the gene PIK3CA and endometrial carcinoma.